Estradiol After Hysterectomy: Estrogen Alone
Roughly one American woman in three has had a hysterectomy by 60. For all of them, one part of hormone therapy is simpler than for everyone else, and for some of them, one part is more urgent. This page is about both.
It assumes you have read, or will read, the estradiol page. What follows is the version for a woman without a uterus.
The simpler part: no progesterone
Progesterone's job in hormone therapy is to protect the lining of the uterus. Estrogen on its own thickens that lining, and over years that thickening can become endometrial cancer — which is why the FDA, when it removed the other boxed warnings from estrogen products in November 2025, kept exactly one: endometrial cancer, on estrogen-alone products, for women who still have a uterus.
If you do not have a uterus, that risk does not exist, and neither does the need for progesterone. Estrogen alone is the standard regimen, and it is the regimen that produced the most reassuring arm of the Women's Health Initiative: fewer breast cancers than placebo over twenty years of follow-up, covered on the breast cancer page.
There are exceptions. A woman whose hysterectomy was for endometriosis may still have endometrial tissue elsewhere, and some clinicians add progesterone in that case. A subtotal hysterectomy that left the cervix behind is sometimes treated the same way. Both are conversations, not rules.
The more urgent part: were the ovaries removed?
A hysterectomy removes the uterus. It may or may not remove the ovaries, and that distinction matters more than the surgery itself.
Ovaries retained. Menopause arrives on roughly its own schedule — often a year or two earlier than it otherwise would have, because the surgery affects blood supply to the ovaries. Without periods there is no obvious marker for when it happens, and symptoms are the signal. The menopause page covers how we read that picture without the usual clue.
Ovaries removed. This is surgical menopause: an abrupt loss of estrogen, on a known date, often years before natural menopause would have occurred. The symptoms are typically more severe than in natural menopause because there is no gradual decline. And the long-term consequences of early estrogen loss — bone, heart, brain — accrue from that date.
For a woman whose ovaries were removed before about 45, the guidance from every major body is the same: estrogen replacement is recommended, at least until the average age of natural menopause, unless there is a specific reason not to. This is not optional optimization. It is replacing something that was removed early, and the evidence for doing so is stronger than for almost any other use of hormone therapy.
Timing, in this situation
The women's HRT page explains why timing matters — starting within ten years of menopause carries the benefit; starting late carries less and risks more. After a hysterectomy the clock is easy to misread.
With ovaries removed, the clock started on the day of surgery. A woman who had her ovaries out at 42 and is now 55 is thirteen years into menopause and outside the standard window — which does not rule therapy out, but changes how it is approached.
With ovaries retained, the clock started whenever they stopped working, which nobody wrote down. Symptoms, and sometimes a hormone panel read carefully, are how we estimate it.
What we check
The baseline panel any hormone plan starts with, plus attention to the things early estrogen loss affects: a bone density scan if one has not been done — see estradiol and bone density — and lipids, including ApoB, because the cardiovascular protection of estrogen is time-sensitive and the risk after surgical menopause is real.
Route is chosen the same way as for anyone else — the patch where clot risk or blood pressure argue for it, topical or cream where they do not.
Frequently asked questions
Usually not. Progesterone protects the uterine lining; with no uterus there is nothing to protect. Exceptions include a history of endometriosis and some subtotal hysterectomies.
On breast cancer, the evidence says yes: the estrogen-alone arm of the WHI showed fewer breast cancers than placebo over twenty years. Clot and stroke risk depend on the route, not on whether progesterone is included.
Major guidelines recommend estrogen replacement after oophorectomy before the age of natural menopause, absent a specific contraindication, at least until around 51. This is one of the strongest indications for hormone therapy that exists.
Without periods there is no marker. Symptoms, age and sometimes a hormone panel are how it is estimated. Ovary-sparing hysterectomy tends to bring menopause a little earlier than it would otherwise have come.
No. Route is chosen on clot risk, blood pressure, skin and preference, as for anyone else.
Possibly, with more care. Starting more than ten years after menopause — which, after oophorectomy, means ten years after the surgery — carries less benefit and more risk, and is an individual decision.
Where this fits in your plan
Start with the Estradiol page and a baseline panel. If your ovaries were removed early, say so at assessment — it moves you up the list.
We measure first. Then we act.
References
- FDA. HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy. November 10 2025 — retention of the endometrial cancer boxed warning on estrogen-alone products.
- Chlebowski RT et al. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the WHI Randomized Clinical Trials. JAMA 2020;324:369–380.
- The Menopause Society. The 2022 Hormone Therapy Position Statement. Menopause 2022;29:767–794 — recommendations on premature and surgical menopause.
- ACOG Committee Opinion No. 774: Opportunistic Salpingectomy as a Strategy for Epithelial Ovarian Cancer Prevention; and ACOG guidance on hormone therapy in primary ovarian insufficiency.
- Rocca WA et al. Long-term risks of early bilateral oophorectomy. Mayo Clinic Proceedings / Menopause —
- Whiteman MK et al. Inpatient hysterectomy surveillance in the United States. American Journal of Obstetrics and Gynecology 2008.
- Back toEstradiol (Clear)
- Estradiol and breast cancer riskThe boxed warning is gone; the question is not. What the WHI actually found for estrogen alone versus combined therapy, in absolute numbers, and what it means for you.Read
- Menopause and perimenopauseWhat the transition does, why a single hormone panel misleads, and what can be excluded and treated.Read
How we write and review our content
ACT 2 Health provides clinician-led care. Treatments are available only to eligible patients following clinical evaluation and within applicable regulations. This content is educational and is not medical advice. Individual results vary.
Compounded medication. Prepared by a licensed compounding pharmacy under a prescription written for you. Compounded medications are not FDA-approved, are not reviewed by the FDA for safety or effectiveness, and are not equivalent to or interchangeable with any branded product. Prescribed only when a licensed provider determines it is medically appropriate.
Care is delivered via telemedicine by healthcare professionals licensed in the state where the patient is located. Services are available only in states where our providers are licensed.